Filliol, Aveline
Saito, Yoshinobu http://orcid.org/0000-0002-0624-0449
Nair, Ajay http://orcid.org/0000-0003-4521-5614
Dapito, Dianne H.
Yu, Le-Xing
Ravichandra, Aashreya
Bhattacharjee, Sonakshi
Affo, Silvia http://orcid.org/0000-0002-9731-3913
Fujiwara, Naoto http://orcid.org/0000-0002-4109-3421
Su, Hua
Sun, Qiuyan
Savage, Thomas M. http://orcid.org/0000-0002-6618-2973
Wilson-Kanamori, John R. http://orcid.org/0000-0002-1372-9912
Caviglia, Jorge M.
Chin, LiKang
Chen, Dongning
Wang, Xiaobo
Caruso, Stefano
Kang, Jin Ku
Amin, Amit Dipak http://orcid.org/0000-0002-2613-2082
Wallace, Sebastian http://orcid.org/0000-0002-1826-0551
Dobie, Ross
Yin, Deqi
Rodriguez-Fiallos, Oscar M. http://orcid.org/0000-0002-5087-3710
Yin, Chuan
Mehal, Adam
Izar, Benjamin http://orcid.org/0000-0003-2379-6702
Friedman, Richard A. http://orcid.org/0000-0002-5136-2998
Wells, Rebecca G. http://orcid.org/0000-0002-6988-4102
Pajvani, Utpal B.
Hoshida, Yujin http://orcid.org/0000-0001-9430-1426
Remotti, Helen E.
Arpaia, Nicholas
Zucman-Rossi, Jessica http://orcid.org/0000-0002-5687-0334
Karin, Michael
Henderson, Neil C. http://orcid.org/0000-0002-2273-4094
Tabas, Ira
Schwabe, Robert F. http://orcid.org/0000-0003-4571-2098
Article History
Received: 26 April 2021
Accepted: 30 August 2022
First Online: 5 October 2022
Competing interests
: B.I. has received honoraria from consulting with Merck, Johnson & Johnson/Janssen Pharmaceuticals, AstraZeneca and Volastra Therapeutics. M.K. is a founder and SAB member of Elgia Pharma and received research support from Merck and Janssen Gossamer Bio. The other authors declare no competing interests.